Kailera Therapeutics is trading at $11.15, down 4.78%; no verified October 15 company announcement or reliable report identified a specific after-hours catalyst.
- Kailera Therapeutics closed October 15 at $11.71 after gaining 9.03% during the regular session.
- The lock-up covering approximately 84.6 million shares ended October 14, a possible supply overhang; no evidence directly links it to this move.
- The latest company release located was October 1 clinical data. The broader market does not clearly explain the decline.